Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc....
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc....
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.